-
1دورية أكاديمية
المؤلفون: E. M. Blazhnova, A. T. Oganesyan, A. R. Ibrahimova, R. B. Balter, T. V. Ivanova
المصدر: Вестник рентгенологии и радиологии, Vol 104, Iss 2, Pp 106-114 (2023)
مصطلحات موضوعية: initial stages of endometriosis, ultrasound imaging, sonography, biomarkers, interleukins, infertility, Medical physics. Medical radiology. Nuclear medicine, R895-920
وصف الملف: electronic resource
العلاقة: https://www.russianradiology.ru/jour/article/view/792Test; https://doaj.org/toc/0042-4676Test; https://doaj.org/toc/2619-0478Test
-
2دورية أكاديمية
المؤلفون: Arturo Rodríguez-Sota, Vishesh Saxena, Jonas Spethmann, Roland Wiesendanger, Roberto Lo Conte, André Kubetzka, Kirsten von Bergmann
مصطلحات موضوعية: Biotechnology, Evolutionary Biology, Ecology, Immunology, Infectious Diseases, Environmental Sciences not elsewhere classified, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, Physical Sciences not elsewhere classified, isotropic metallic surface, different cluster sizes, densely packed one, assembly typically leads, mn forms trimers, reconstructed monolayer islands, antiferromagnetic mn islands, mn trimer clusters, reconstructed islands, clusters supported, various ways, solid substrates, selected soft, pseudomorphic film, prime candidates, often used, nearest neighbors, monodisperse particles, magnetic state, landing methods, initial stages
الإتاحة: https://doi.org/10.1021/acsnano.3c11459.s001Test
https://figshare.com/articles/journal_contribution/Phase_Coexistence_of_Mn_Trimer_Clusters_and_Antiferromagnetic_Mn_Islands_on_Ir_111_/25008632Test -
3دورية أكاديمية
المؤلفون: Jian Yu, Haidy Metwally, Jennifer Kolwich, Hailey Tomm, Rachel Klotz, Chang Liu, J. C. Yves LeBlanc, Thomas R. Covey, Avena C. Ross, Richard D. Oleschuk
مصطلحات موضوعية: Biochemistry, Pharmacology, Biotechnology, Immunology, Marine Biology, Inorganic Chemistry, Mathematical Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, potential natural products, mostly performed manually, ambient mass spectrometry, algorithm uses mass, natural product screening, spectral screening reliability, principal component analysis, based spectral analysis, analyze ms spectra, spectral screening, important component, complex spectra, based metabolomics, based application, unlike chromatography, straightforward tool, scoring plots, relies heavily, quickly locate, proteomics approaches, large amounts, initial stages
الإتاحة: https://doi.org/10.1021/jasms.3c00322.s001Test
https://figshare.com/articles/journal_contribution/SpectraX_A_Straightforward_Tool_for_Principal_Component_Analysis-Based_Spectral_Analysis/24994572Test -
4دورية أكاديمية
مصطلحات موضوعية: Evolutionary Biology, Cancer, Inorganic Chemistry, Space Science, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, Physical Sciences not elsewhere classified, hydrogen tungsten bronze, cumulative concentration fractions, 1s core levels, bombardment time correlates, 5 + sup, 3 sub, 2 sub, 0 sup, tungsten trioxide reduction, oxide reduction mechanism, – h bonds, energy hydrogen bombardment, energy h, reduction process, reduction proceeds, valence band, thin films, room temperature, oxidation states, oxidation state, molecules removes, lower oxides, initial stages
-
5دورية أكاديمية
المؤلفون: Felipe Lipsky, Luis Henrique da Silveira Lacerda, Lourdes Gracia, Beatriz G. Foschiani, Marcelo Assis, Mónica Oliva, Elson Longo, Juan Andrés, Miguel A. San-Miguel
مصطلحات موضوعية: Biochemistry, Cell Biology, Physiology, Developmental Biology, Infectious Diseases, Environmental Sciences not elsewhere classified, Biological Sciences not elsewhere classified, Information Systems not elsewhere classified, reactive oxygen species, energetically favorable pathway, hydroxyl (• oh, enhanced degradation process, 4 sub, 3 sub, 2 sub, superoxide (•, catalytic process, new perspective, multifunctional competence, molecules regulate, initial stages, experimental results, efficiently activates, bactericidal activity, atomic level
الإتاحة: https://doi.org/10.1021/acs.jpcc.3c06321.s001Test
https://figshare.com/articles/journal_contribution/A_Tale_of_Reactive_Oxygen_Species_on_the_Ag_sub_3_sub_PO_sub_4_sub_110_Surface/24596413Test -
6دورية أكاديمية
مصطلحات موضوعية: Biophysics, Biochemistry, Microbiology, Genetics, Molecular Biology, Inorganic Chemistry, Science Policy, Biological Sciences not elsewhere classified, Mathematical Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, Information Systems not elsewhere classified, short time span, selective proteasomal degradation, raised interest thanks, novel therapeutic modality, experimentally determined structures, computationally sparing approach, provides sound results, computed tc structure, new computational method, promising results, 3d structure, undesired proteins, ternary complexes, selected set, retrospective analysis, protac drugs, modeling protac, method ’, initial stages
الإتاحة: https://doi.org/10.1021/acsmedchemlett.3c00362.s003Test
https://figshare.com/articles/journal_contribution/DegraderTCM_A_Computationally_Sparing_Approach_for_Predicting_Ternary_Degradation_Complexes/24802906Test -
7دورية أكاديمية
المؤلفون: Bette Beament, Daniel Britton, Thomas Malcomson, Geoffrey R. Akien, Nathan R. Halcovitch, Michael P. Coogan, Rachel H. Platel
مصطلحات موضوعية: Biophysics, Biochemistry, Medicine, Microbiology, Molecular Biology, Chemical Sciences not elsewhere classified, tertiary amine center, ligands incorporate benzyl, ligands designed around, >- di -<, controlling copolymer microstructure, control copolymer microstructure, ε ‑ caprolactone, copolymer microstructure, >- hydroxy, copolymer gave, copolymer formation, transesterification (<, suppressed ε, solution states, selective transesterification, pyridyl substituents, pyridyl groups, propagation reactions, monomodal trace, initial stages, fully characterized, exclusion chromatography, equimolar amounts, either transesterification
الإتاحة: https://doi.org/10.1021/acs.inorgchem.3c03120.s001Test
https://figshare.com/articles/journal_contribution/Selective_Transesterification_to_Control_Copolymer_Microstructure_in_the_Ring-Opening_Copolymerization_of_Lactide_and_Caprolactone_by_Lanthanum_Complexes/24885636Test -
8دورية أكاديمية
المصدر: Revista de Investigação e Divulgação em Educação Matemática ; v. 7 n. 1 (2023): Janeiro-Dezembro ; 2594-4673
مصطلحات موضوعية: Formação de professores, Anos iniciais, Saberes docentes, Conhecimento matemático, Teacher instruction, Initial stages, Educator knowledge, Mathematical knowledge
وصف الملف: application/pdf
العلاقة: https://periodicos.ufjf.br/index.php/ridema/article/view/41105/26213Test; https://periodicos.ufjf.br/index.php/ridema/article/view/41105Test
الإتاحة: https://doi.org/10.34019/2594-4673.2023.v7.41105Test
https://periodicos.ufjf.br/index.php/ridema/article/view/41105Test -
9دورية أكاديمية
المؤلفون: E. A. Katunina, Z. A. Zalyalova, D. V. Pokhabov, M. Z. Ivanova, A. M. Semenova, Е. А. Катунина, З. А. Залялова, Д. В. Похабов, М. З. Иванова, А. М. Семенова
المساهمون: This article has been supported by Servier, Статья спонсируется компанией «Сервье»
المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 15, No 3 (2023); 95-103 ; Неврология, нейропсихиатрия, психосоматика; Vol 15, No 3 (2023); 95-103 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-3
مصطلحات موضوعية: пирибедил, initial stages, dopamine receptor agonists, piribedil, начальные стадии, агонисты дофаминовых рецепторов
وصف الملف: application/pdf
العلاقة: https://nnp.ima-press.net/nnp/article/view/2036/1542Test; Tysnes O-B, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017 Aug;124(8):901-5. doi:10.1007/s00702-017-1686-y. Epub 2017 Feb 1.; Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003 MarApr;24(2):197-211. doi:10.1016/s01974580(02)00065-9; Pinter B, Diem-Zangerl A, Wenning GK, et al. Mortality in Parkinson’s disease: a 38-year follow-up study. Mov Disord. 2015 Feb;30(2):266-9. doi:10.1002/mds.26060. Epub 2014 Dec 1. Erratum in: Mov Disord. 2017 Jan;32(1):178.; Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007 Jan 30;68(5):384-6. doi:10.1212/01.wnl.0000247740.47667.03. Epub 2006 Nov 2.; Lunati A, Lesage S, Brice A. The genetic landscape of Parkinson’s disease. Rev Neurol (Paris). 2018 Nov;174(9):628-43. doi:10.1016/j.neurol.2018.08.004. Epub 2018 Sep 21.; Hawkes CH, Del Tredici K, Braak H. Parkinson’s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol. 2007 Dec;33(6):599-614. doi:10.1111/j.13652990.2007.00874.x. Epub 2007 Oct 24.; Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna). 2003 May;110(5):517-36. doi:10.1007/s00702-002-0808-2; Borghammer P. How does Parkinson’s disease begin? Perspectives on neuroanatomical pathways, prions, and histology. Mov Disord. 2018 Jan;33(1):4857. doi:10.1002/mds.27138. Epub 2017 Aug 26.; Holmqvist S, Chutna O, Bousset L, et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. 2014 Dec;128(6):80520. doi:10.1007/s00401-014-1343-6. Epub 2014 Oct 9.; Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P. Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann Neurol. 2016 Jun;79(6):940-9. doi:10.1002/ana.24648. Epub 2016 Apr 9.; Pan-Montojo F, Anichtchik O, Dening Y, et al. Progression of Parkinson’s disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One. 2010 Jan 19;5(1):e8762. doi:10.1371/journal.pone.0008762; Svensson E, Horvath-Puho E, Thomsen RW, et al. Vagotomy and subsequent risk of Parkinson’s disease. Ann Neurol. 2015 Oct;78(4):522-9. doi:10.1002/ana.24448. Epub 2015 Jul 17.; Liu B, Fang F, Pedersen NL, et al. Vagotomy and Parkinson disease: A Swedish register-based matched-cohort study. Neurology. 2017 May 23;88(21):1996-2002. doi:10.1212/WNL.0000000000003961. Epub 2017 Apr 26.; Lionnet A, Leclair-Visonneau L, Neunlist M, et al. Does Parkinson’s disease start in the gut? Acta Neuropathol. 2018 Jan;135(1):1-12. doi:10.1007/s00401-0171777-8. Epub 2017 Oct 16.; Gjerloff T, Fedorova T, Knudsen K, et al. Imaging acetylcholinesterase density in peripheral organs in Parkinson’s disease with 11C-donepezil PET. Brain. 2015 Mar;138(Pt 3):653-63. doi:10.1093/brain/awu369. Epub 2014 Dec 23.; Knudsen K, Fedorova TD, Hansen AK, et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurol. 2018 Jul;17(7):618-28. doi:10.1016/S14744422(18)30162-5. Epub 2018 Jun 1.; Iranzo A, Fernandez-Arcos A, Tolosa E, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One. 2014 Feb 26;9(2):e89741. doi:10.1371/journal.pone.0089741; Miyamoto T, Miyamoto M, Inoue Y, et al. Reduced cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. Neurology. 2006 Dec 26;67(12):2236-8. doi:10.1212/01.wnl.0000249313.25627.2e; Kashihara K, Imamura T, Shinya T. Cardiac 123I-MIBG uptake is reduced more markedly in patients with REM sleep behavior disorder than in those with early stage Parkinson’s disease. Parkinsonism Relat Disord. 2010 May;16(4):252-5. doi:10.1016/j.parkreldis.2009.12.010. Epub 2010 Jan 25.; Orimo S, Yogo M, Nakamura T, et al. (123)I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in α-synucleinopathies. Ageing Res Rev. 2016 Sep;30:122-33. doi:10.1016/j.arr.2016.01.001. Epub 2016 Feb 2.; Knudsen K, Fedorova TD, Horsager J, et al. Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson’s Disease Subtypes. J Parkinsons Dis. 2021;11(4):1677-87. doi:10.3233/JPD-212761; Horsager J, Andersen KB, Knudsen K, et al. Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study. Brain. 2020 Oct 1;143(10):3077-88. doi:10.1093/brain/awaa238; Borghammer P. The α-synuclein origin and Connectome Model (SOC model) of Parkinson’s disease: Explaining motor asymmetry, non-motor phenotypes, and cognitive decline. J Parkinson’s Dis. 2021;11(2):455-74. doi:10.3233/JPD-202481; Berg D, Postuma RB, Adler CH, et al. MDS research criteria for Prodromal Parkinson’s disease. Mov Disord. 2015 Oct;30(12):1600-11. doi:10.1002/mds.26431; Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015 Oct;30(12):1591-601. doi:10.1002/mds.26424; Иллариошкин СН, Левин ОС, редакторы. Руководство по диагностике и лечению болезни Паркинсона. Москва: ООО «ИПК Парето-Принт»; 2017. 336 с.; Селихова МВ, Катунина ЕА, Воун А. Позитронная эмиссионная и однофотонная эмиссионная компьютерная томография в оценке состояния моноаминергических систем мозга при экстрапирамидных расстройствах. Анналы клинической и экспериментальной неврологии. 2019;13(2):69-78. doi:10.25692/ACEN.2019.2.8; Болезнь Паркинсона, вторичный паркинсонизм и другие заболевания, проявляющиеся синдромом паркинсонизма. Клинические рекомендации. 2021. Доступно по ссылке: https://cr.minzdrav.gov.ru/recomend/716_1Test Bolezn’ Parkinsona, vtorichnyi parkinsonism i drugie zabolevaniya, proyavlyayushchiesya sindromom parkinsonizma; Нарушения обмена меди (болезнь Вильсона). Клинические рекомендации. 2021. Доступно по ссылке: https://cr.minzdrav.gov.ru/recomend/376_2Test; Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-es recommendations for the diagnosis of Parkinson’s disease. Eur J Neurol. 2013 Jan;20(1):16-34. doi:10.1111/ene.12022. Erratum in: Eur J Neurol. 2013 Feb;20(2):406.; D Med Collaborative Group; Gray R, Ives N, Rick C, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014 Sep 27;384(9949):1196-205. doi:10.1016/S0140-6736(14)60683-8. Epub 2014 Jun 11. Erratum in: Lancet. 2014 Sep 27;384(9949):1186.; Bergamasco B, Frattola L, Muratorio A, et al. Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomized, double-blind, placebo-controlled study. Acta Neurol Scand. 2000 Jun;101(6):372-80. doi:10.1034/j.16000404.2000.90295a.x; Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study Group. Neurology. 1997 Sep;49(3):724-8. doi:10.1212/wnl.49.3.724. Erratum in: Neurology. 1998 Mar;50(3):838.; Finotti N, Castagna L, Moretti A, Marzatico F. Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment. Pharmacol Res. 2000;42(4):287-91. doi:10.1006/phrs.2000.0690; Le W-D, Jankovic J. Are dopamine receptors agonists neuroprootective in Parkinson’s disease? Drugs Aging. 2001;18(6):389-96. doi:10.2165/00002512-200118060-00001; Nishibayashi S, Asanuma M, Kohno M, et al. Scavenging effects of dopamine agonists on nitric oxide radicals. J Neurochem. 1996;67(5):2208-11. doi:10.1046/j.14714159.1996.67052208.x; Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. New Engl J Med. 2000;342(20):1484-91. doi:10.1056/nejm200005183422004; Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002 Apr 3;287(13):1653-61. doi:10.1001/jama.287.13.1653; Whone AL, Watts RL, Stoessl AJ, et al; REAL-PET Study Group. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003 Jul;54(1):93-101. doi:10.1002/ana.10609; Schapira A, Albrecht S, Barone P, et al. P1.203 immediate vs. delayed-start pramipexole in early Parkinson’s disease: The proud study. Parkinsonism Relat Disord. 2009;15:S81. doi:10.1016/s1353-8020(09)70325-6; Gerlach M, Double K, Arzberger T, et al. Dopamine receptor agonists in current clinical use: Comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transmis. 2003;110(10):1119-27. doi:10.1007/s00702-003-0027-5; Etminan M, Samii A, Takkouche B, Rochon PA. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson’s disease. Drug Saf. 2001;24(11):863-8. doi:10.2165/00002018200124110-00007; Antonini A, Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson’s disease. Drug Saf. 2009;32(6):475-88. doi:10.2165/00002018-200932060-00004; Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson’s disease. Arch Neurol. 2010 May;67(5):589-95. doi:10.1001/archneurol.2010.65; Isaias IU, Siri C, Cilia R, et al. The relationship between impulsivity and impulse control disorders in Parkinson’s disease. Mov Disord. 2008;23(3):411-5. doi:10.1002/mds.21872; Weintraub D, Hoops S, Shea JA, et al. Validation of the questionnaire for impulsivecompulsive disorders in Parkinson’s disease. Mov Disord. 2009;24(10):1461-7. doi:10.1002/mds.22571; Weintraub D, Rektorova I. Impulse control disorders and related behaviors. In: D Aarsland, J Cummings, D Weintraub, K Chaudhuri, editors. Neuropsychiatric and Cognitive Changes in Parkinson’s Disease and Related Movement Disorders: Diagnosis and Management. Cambridge: Cambridge University Press; 2013. P. 140-52. doi:10.1017/CBO9781139856669.014; Joutsa J, Martikainen K, Vahlberg T, et al. Impulse control disorders and depression in Finnish patients with Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(2):155-60. doi:10.1016/j.parkreldis.2011.09.007; Antonini A, Barone P, Bonuccelli U, et al. Icarus study: Prevalence and clinical features of impulse control disorders in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2017;88(4):317-24. doi:10.1136/jnnp-2016315277; Thorlund K, Wu P, Druyts E, et al. Nonergot dopamine-receptor agonists for treating Parkinson’s disease – a network meta-analysis. Neuropsychiatr Dis Treatm. 2014;2014:767-76. doi:10.2147/ndt.s60061; LeWitt PA, Boroojerdi B, MacMahon D, et al. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson’s disease. Clin Neuropharmacol. 2007;30(5):256-65. doi:10.1097/wnf.0b013e318154c7c4; Millan MJ. From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson’s disease. Pharmacol Ther. 2010;128(2):229-73. doi:10.1016/j.pharmthera.2010.06.002; Gobert A, Di Cara B, Cistarelli L, Millan MJ. Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of α2aadrenoceptors: A dialysis comparison to Talipexole and Quinelorane in the absence of acetylcholinesterase inhibitors. J Pharmacol Exper Ther. 2003;305(1):338-46. doi:10.1124/jpet.102.046383; Delaville C, Deurwaerdere PD, Benazzouz A. Noradrenaline and Parkinson’s disease. Front Syst Neurosci. 2011 May 18;5:31. doi:10.3389/fnsys.2011.00031. eCollection 2011.; Djaldetti R, Mosberg-Galili R, Sroka H, et al. Camptocormia (Bent Spine) in patients with Parkinson’s disease characterization and possible pathogenesis of an unusual phenomenon. Mov Disord. 1999;14(3):443-7. doi:10.1002/1531-8257(199905)14:33.0.co;2-g; Suzuki M, Hirai T, Ito Y, et al. Pramipexole-induced antecollis in Parkinson’s disease. J Neurol Sci. 2008;264(1-2):195-7. doi:10.1016/j.jns.2007.08.008; Calzi F, Bellasio R, Guiso G, et al. Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo. Eur J Pharmacol. 1997;338(2):185-90. doi:10.1016/s0014-2999(97)81947-4; Munchau A. Pharmacological treatment of Parkinson’s disease. Postgrad Med J. 2000;76(900):602-10. doi:10.1136/pmj.76.900.602; Rascol O, Dubois B, Caldas AC, et al. Early Piribedil monotherapy of Parkinson’s disease: A planned seven-month report of the Regain Study. Mov Disord. 2006;21(12):2110-5. doi:10.1002/mds.21122; Rondot P, Ziegler M. Activity and acceptability of Piribedil in Parkinson’s disease: A multicentre study. J Neurol. 1992;239 Suppl 1:S28-34. doi:10.1007/BF00819564; Chen X, Ren C, Li J, et al. The efficacy and safety of Piribedil relative to pramipexole for the treatment of early Parkinson’s disease: A systematic literature review and network meta-analysis. Clin Neuropharmacol. 2020;43(4):100-6. doi:10.1097/wnf.0000000000000400; Aarsland D, Bronnick K, Larsen JP, et al. Cognitive impairment in incident, untreated Parkinson’s disease: The Norwegian Parkwest Study. Neurology. 2009;72(13):1121-6. doi:10.1212/01.wnl.0000338632.00552.cb; Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson’s disease: A Multicenter pooled analysis. Neurology. 2010;75(12):1062-9. doi:10.1212/wnl.0b013e3181f39d0e; Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson’s disease: Critical review of pd-MCI. Mov Disord. 2011;26(10):1814-24. doi:10.1002/mds.23823; Yarnall AJ, Breen DP, Duncan GW, et al. Characterizing mild cognitive impairment in incident Parkinson’s disease: The Icicle-PD Study. Neurology. 2014;82(4):308-16. doi:10.1212/wnl.0000000000000066; Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson’s disease. J Neurol Sci. 2010;289(1-2):18-22. doi:10.1016/j.jns.2009.08.034; Buter TC, van den Hout A, Matthews FE, et al. Dementia and survival in Parkinson’s disease: A 12-year population study. Neurology. 2008;70(13):1017-22. doi:10.1212/01.wnl.0000306632.43729.24; Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson’s disease: Diagnosis, biomarkers, and treatment. Lancet Neurol. 2012;11(8):697707. doi:10.1016/s1474-4422(12)70152-7; Федорова НВ, Артемьева ЕГ, Чигирь ИП, Левин ОС. Применение пронорана (пирибедила) при болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2003;103(9):71-2.; Пилипович АА, Голубев ВЛ. Влияние Пронорана на когнитивные и аффективные нарушения при болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2005;105(4):41-7.; Ollat H. Dopaminergic insufficiency reflecting cerebral ageing: Value of a dopaminergic agonist, Piribedil. J Neurol. 1992;239(S1):13-6. doi:10.1007/bf00819561; Valdes P, Schneider BL. Gene therapy: A promising approach for neuroprotection in Parkinson’s disease? Front Neuroanat. 2016 Dec 20;10:123. doi:10.3389/fnana.2016.00123.eCollection2016.; Brocco M, Dekeyne A, Papp M, Millan MJ. Antidepressant-like properties of the anti-parkinson agent, Piribedil, in rodents: Mediation by dopamine D2 receptors. Behav Pharmacol. 2006;17(7):559-72. doi:10.1097/01.fbp.0000236267.41806.5b; Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex – basal ganglia circuits. Cerebral Cortex. 2006;16(7):916-28. doi:10.1093/cercor/bhj043; Dujardin K, Defebvre L. Apathy in Parkinson’s disease: What are the underlying mechanisms? Neurology. 2012;79(11):1082-3. doi:10.1212/wnl.0b013e3182698dd4; Starkstein SE. Apathy in Parkinson’s disease: Diagnostic and Etiological Dilemmas. Mov Disord. 2012;27(2):174-8. doi:10.1002/mds.24061; Pluck GC. Apathy in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):636-42. doi:10.1136/jnnp.73.6.636; Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord. 2009;24(15):2175-86. doi:10.1002/mds.22589; Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573-80. doi:10.1016/s1474-4422(10)70106-x; Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in Advanced Parkinson’s Disease. N Engl J Med. 2003;349(20):1925-34. doi:10.1056/nejmoa035275; Funkiewiez A. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75(6):834-9. doi:10.1136/jnnp.2002.009803; Czernecki V, Schüpbach M, Yaici S, et al. Apathy following subthalamic stimulation in Parkinson’s disease: A dopamine responsive symptom. Mov Disord. 2008;23(7):964-9. doi:10.1002/mds.21949; Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: A randomised, Multicentre Study. Lancet Neurol. 2008;7(7):605-14. doi:10.1016/s1474-4422(08)70114-5; Remy P, Doder M, Lees A, et al. Depression in Parkinson’s disease: Loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128(6):131422. doi:10.1093/brain/awh445; Thobois S, Ardouin C, Lhommee E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson’s disease: Predictors and underlying mesolimbic denervation. Brain. 2010;133(4):1111-27. doi:10.1093/brain/awq032; Schrag A. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry. 2000;69(3):30812. doi:10.1136/jnnp.69.3.308; Voon V, Fernagut P-O, Wickens J, et al. Chronic dopaminergic stimulation in Parkinson’s disease: From Dyskinesias to impulse control disorders. Lancet Neurol. 2009;8(12):1140-9. doi:10.1016/s14744422(09)70287-x; Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson’s disease: Dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464-74. doi:10.1016/s1474-4422(09)70068-7; Thobois S, Lhommee E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with Piribedil. Brain. 2013;136(5):1568-77. doi:10.1093/brain/awt067; Paus S, Brecht HM, Köster J, et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson’s disease. Mov Disord. 2003;18(6):659-67. doi:10.1002/mds.10417; Borek LL, Amick MM, Friedman JH. Non-motor aspects of Parkinson’s disease. CNSSpectrums. 2006;11(7):541-54. doi:10.1017/s1092852900013560; Tracik F, Ebersbach G. Sudden daytime sleep onset in Parkinson’s disease: Polysomnographic recordings. Mov Disord. 2001;16(3):500-6. doi:10.1002/mds.1083; Ulivelli M, Rossi S, Lombardi C, et al. Polysomnographic characterization of pergolide-induced sleep attacks in idiopathic PD. Neurology. 2002;58(3):462-5. doi:10.1212/wnl.58.3.462; Allcock LM, Rowan EN, Steen IN, et al. Impaired attention predicts falling in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(2):110-5. doi:10.1016/j.parkreldis.2008.03.010; Meindorfner C, Körner Y, Möller JC, et al. Driving in Parkinson’s disease: Mobility, accidents, and sudden onset of sleep at the wheel. Mov Disord. 2005;20(7):832-42. doi:10.1002/mds.20412; Drouot X, Moutereau S, Nguyen JP, et al. Low levels of ventricular CSF orexin/hypocretin in Advanced PD. Neurology. 2003;61(4):540-3. doi:10.1212/01.wnl.0000078194.53210.48; Poewe W, Hogl B. Sleep and Parkinson’s disease. Editional review. Curr Opin Neurol. 2000 Aug;13(4):423-6. doi:10.1097/00019052200008000-00009; Verbaan D, van Rooden SM, Visser M, et al. Nighttime sleep problems and daytime sleepiness in Parkinson’s disease. Mov Disord. 2008;23(1):35-41. doi:10.1002/mds.21727; Wood LD. Clinical Review and treatment of select adverse effects of dopamine receptor agonists in Parkinson’s disease. Drugs Aging. 2010;27(4):295-310. doi:10.2165/11318330000000000-00000; Monaca C, Duhamel A, Jacquesson JM, et al. Vigilance troubles in Parkinson’s disease: A subjective and objective polysomnographic study. Sleep Med. 2006;7(5):448-53. doi:10.1016/j.sleep.2005.12.002; Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel: Motor Vehicle Mishaps in persons taking pramipexole and Ropinirole. Neurology. 1999 Jun 10;52(9):1908-10. doi:10.1212/wnl.52.9.1908; Eggert K, Еhlwein C, Kassubek J, et al. Influence of the nonergot dopamine agonist Piribedil on vigilance in patients with Parkinson’s disease and excessive daytime sleepiness (PiViCog-PD). Clin Neuropharmacol. 2014;37(4):116-22. doi:10.1097/wnf.0000000000000041; Millan MJ, Maiofiss L, Cussac D, et al. Differential actions of Antiparkinson agents at multiple classes of monoaminergic receptor. i. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exper Ther. 2002;303(2):791-804. doi:10.1124/jpet.102.039867; Katunina EA, Blokhin V, Nodel MR, et al. Searching for biomarkers in the blood of patients at risk of developing Parkinson’s disease at the Prodromal Stage. Int J Mol Sci. 2023;24(3):1842. doi:10.3390/ijms24031842; https://nnp.ima-press.net/nnp/article/view/2036Test
الإتاحة: https://doi.org/10.14412/2074-2711-2023-3-95-103Test
https://doi.org/10.14412/2074-2711-2023-3Test
https://doi.org/10.1007/s00702-017-1686-yTest
https://doi.org/10.1016/s01974580Test(02)00065-9
https://doi.org/10.1002/mds.26060Test
https://doi.org/10.1212/01.wnl.0000247740.47667.03Test
https://doi.org/10.1016/j.neurol.2018.08.004Test
https://doi.org/10.1111/j.13652990.2007.00874.xTest
https://doi.org/10.1007/s00702-002-0808-2Test
https://doi.org/10.1007/s00401-014-1343-6Test -
10مؤتمر
المؤلفون: B, Acevedo, Nestor Valero Silva
مصطلحات موضوعية: I200 - Information systems, General description, General method, Heterogeneous ensembles, Initial approximation, Initial stages, Method of analysis, Michel Foucault, Soft systems methodology